Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Arm Study of Lorlatinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI)

NCT04362072 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04362072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04362072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Arm Study of Lorlatinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI)
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
September 29, 2020
Completion date
October 23, 2024
Enrollment
71 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung